ストックスクリーナーアプリを入手
95.91
1.47%
1.098
前日終値:
$94.81
開ける：
$94.98
24時間の取引高:
157.85K
Relative Volume:
0.26
時価総額：
$5.94B
収益：
$434.41M
当期純損益:
$-128.05M
株価収益率:
-10.44
EPS:
-9.19
ネットキャッシュフロー:
$-250.52M
1週間 パフォーマンス:
+0.58%
1か月 パフォーマンス:
+12.37%
6か月 パフォーマンス:
-7.17%
1年 パフォーマンス:
+45.10%
1日の値動き範囲:
$92.97
$96.26
1週間の範囲:
$88.05
$96.34
52週間の値動き範囲:
$65.68
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
名前
Blueprint Medicines Corp
セクター
電話
617-374-7580
住所
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BPMC | 96.26 | 5.94B | 434.41M | -128.05M | -250.52M | -9.19 |
| VRTX | 447.62 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.21 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.16 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.85 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-10-27 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 繰り返されました | Needham | Buy |
| 2023-07-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-11-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2022-07-08 | 開始されました | Oppenheimer | Outperform |
| 2022-06-27 | 開始されました | Wells Fargo | Underweight |
| 2022-06-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-06-01 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-01 | 開始されました | Citigroup | Neutral |
| 2022-02-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | アップグレード | Stifel | Hold → Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 再開されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-11-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-02 | ダウングレード | Jefferies | Buy → Hold |
| 2020-10-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Equal Weight |
| 2020-03-17 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-11-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-09-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 開始されました | Piper Jaffray | Neutral |
| 2019-08-15 | 再開されました | Raymond James | Mkt Perform |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-05-23 | 再開されました | Goldman | Buy |
| 2019-04-03 | 開始されました | Morgan Stanley | Overweight |
| 2018-09-25 | 開始されました | Leerink Partners | Outperform |
| 2017-12-11 | 繰り返されました | Goldman | Buy |
すべてを表示
Blueprint Medicines Corp (BPMC) 最新ニュース
Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com
Blueprint Medicines initiated with an Overweight at JPMorgan - MSN
Victory Capital Management Inc. Trims Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat
HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Yahoo Finance
Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat
Mastocytosis Treatment Market Forecasted for Major Expansion - openPR
Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat
M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat
Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com
Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve
Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World
Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance
Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks
Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com Australia
Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire
When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St
Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? - Yahoo Finance UK
UBS Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC) - Defense World
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
Analyst Ratings For Blueprint Medicines - Benzinga
Blueprint Medicines Corp (BPMC) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):